Distancing design of phase III trials from drug company influence
Moynihan and colleagues propose ways to produce healthcare evidence independent of commercial interests.1The design of pivotal phase III clinical trials is typically discussed in advance between…
Read Original Article: Distancing design of phase III trials from drug company influence »
